Sanofi (SNY) wins FDA label expansion for its MenQuadfi meningococcal vaccine for use in infants as young as six weeks. Read ...

HHS Secretary Robert F. Kennedy Jr. threatened to bar NIH scientists from publishing in leading medical journals, saying the ...

The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now ...

French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants ...

Sanofi (SNY)'s share was trading at $51.06 ... by deep public-sector distribution—generated €2.25 billion, and MenQuadfi, a meningitis vaccine, posted 50.5% growth. Despite some expected ...

Sanofi Eyes Extension of Meningococcal Disease Shot to Infants, Toddlers Sanofi’s meningococcal disease vaccine MenQuadfi is currently approved for the primary immunization of children aged two years ...

While it’s largely preventable through vaccines such as Sanofi’s own MenQuadfi, infection of the most severe form, bacterial meningitis, can be fatal within just 24 hours and remains a ...

Who Are the Leading Players in the MenQuadfi Market? The market's expansion is driven by leading industry participants, notably Sanofi S.A. Their ongoing commitment to vaccine development and ...

Meningitis remains a significant health problem, affecting 2.5 million people annually and causing death and disability despite the availability of vaccines such as Sanofi’s MenQuadfi that ...

Sanofi-Aventis U.S. was hit with a consumer class action Thursday in California Northern District Court over the company's hydrocortisone-based products. The complaint, which was brought by ...